Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP 3

Novo Nordisk · Phase 3 · Completed · Enrollment 611

NCT03611582

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutiden/rn/rn/rn/r
Semaglutide placebon/rn/rn/rn/r
Semaglutide 2.4 mg, in trialn/rn/rn/rn/r
Placebo, in trialn/rn/rn/rn/r

Not shown

  • Semaglutide: endpoint not reported
  • Semaglutide placebo: endpoint not reported
  • Semaglutide 2.4 mg, in trial: endpoint not reported
  • Placebo, in trial: endpoint not reported